Q-omics provides the consensus-scored S100A5 profile across patient tissues and cancer cell-line models. S100A5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, S100A5 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, S100A5 RNA expression shows 14,695 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where S100A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100A5 survival associations across molecular data types. S100A5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100A5 RNA expression–survival associations across cancer types. High S100A5 expression shows unfavorable associations in KIRC, MESO, LGG and UCEC, but favorable associations in LUSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for S100A5 RNA expression.
This table summarizes S100A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for S100A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100A5 shows lower tumor expression in KIRC and higher tumor expression in THCA, COAD, HNSC, PAAD and LUAD. The KIRC box plot shows higher S100A5 RNA expression in normal versus tumor tissue (log2 FC = −1.278, t-test p < 0.001).
This table shows molecular features associated with S100A5 in patient tissues and cancer cell lines. In patient samples, S100A5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, S100A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
